The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia

PURPOSE: To establish a proof-of-concept for the efficacy of the anti-CD38 antibody daratumumab in the poor prognosis CD38(+) CLL subtype. EXPERIMENTAL DESIGN: The mechanism of action of daratumumab was assessed in CLL primary cells and cell lines using peripheral blood mononuclear cells to analyze...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Matas-Céspedes, Alba, Vidal-Crespo, Anna, Rodriguez, Vanina, Villamor, Neus, Delgado, Julio, Giné, Eva, Roca-Ho, Heleia, Menéndez, Pablo, Campo, Elías, López-Guillermo, Armando, Colomer, Dolors, Roué, Gaël, Wiestner, Adrian, Parren, Paul W.H.I., Doshi, Parul, van Bueren, Jeroen Lammerts, Pérez-Galán, Patricia
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354986/
https://ncbi.nlm.nih.gov/pubmed/27637890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2095
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares